The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis

BACKGROUND: L-asparaginase is a key component of treatment for patients with acute lymphoblastic leukaemia (ALL) in the UK. Commonly used forms of asparaginase are native E. coli-derived asparaginase (native asparaginase) and pegaspargase in first-line combination therapy, and native Erwinia chrysan...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xingdi, Wildman, Kingsley P., Basu, Subham, Lin, Peggy L., Rowntree, Clare, Saha, Vaskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935472/
https://www.ncbi.nlm.nih.gov/pubmed/31885053
http://dx.doi.org/10.1186/s13561-019-0257-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935472/
https://www.ncbi.nlm.nih.gov/pubmed/31885053
http://dx.doi.org/10.1186/s13561-019-0257-3

Ejemplares similares